KR100589429B1 - Process for preparation of quinolone derivatives substituted by aminopyridyl moieties at n-1 site - Google Patents

Process for preparation of quinolone derivatives substituted by aminopyridyl moieties at n-1 site Download PDF

Info

Publication number
KR100589429B1
KR100589429B1 KR1020040068860A KR20040068860A KR100589429B1 KR 100589429 B1 KR100589429 B1 KR 100589429B1 KR 1020040068860 A KR1020040068860 A KR 1020040068860A KR 20040068860 A KR20040068860 A KR 20040068860A KR 100589429 B1 KR100589429 B1 KR 100589429B1
Authority
KR
South Korea
Prior art keywords
amino
oxo
difluoro
preparation
derivative
Prior art date
Application number
KR1020040068860A
Other languages
Korean (ko)
Other versions
KR20060020106A (en
Inventor
박태호
이상호
윤창수
하영환
오정훈
Original Assignee
한국화학연구원
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 한국화학연구원 filed Critical 한국화학연구원
Priority to KR1020040068860A priority Critical patent/KR100589429B1/en
Publication of KR20060020106A publication Critical patent/KR20060020106A/en
Application granted granted Critical
Publication of KR100589429B1 publication Critical patent/KR100589429B1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

본 발명은 N-1 위치에 아미노피리딜기가 치환된 퀴놀론 유도체를 제조하는 방법에 관한 것으로, 본 발명에 따라 3-옥소-프로피온산 에틸 에스테르 유도체와 트리에틸오르소포메이트의 반응으로 생성된 에톡시에틸렌 유도체에 2-아미노-3,5,6-트리플루오르피리딘을 도입시킨 후 이를 고리화하고 아미노기를 도입시키는 단계를 포함하는 하기 화학식 1의 N-1 위치에 3,5-다이플루오르-6-아미노피리딜기가 치환된 퀴놀론 유도체 제조 방법은, 산업적 적용이 용이한 공정을 통해 N-1 위치에 3,5-다이플루오르-6-아미노피리딜기가 치환된 퀴놀론 유도체를 고수율로 제조할 수 있으므로 CCR(cellular chemokine receptor: 세포화학수용체)5 모듈레이터(modulator)의 제조 뿐만 아니라 감염증 치료제(anti-infective agents)의 제조 등에 유용하게 활용될 수 있다.The present invention relates to a method for preparing a quinolone derivative substituted with an aminopyridyl group at the N-1 position, wherein the ethoxyethylene produced by the reaction of a 3-oxo-propionic acid ethyl ester derivative and triethylorthoformate according to the present invention 3,5-difluoro-6-amino at the N-1 position of the formula (1) comprising the step of introducing 2-amino-3,5,6-trifluoropyridine to the derivative followed by cyclization and introducing an amino group In the method for preparing a pyridyl-substituted quinolone derivative, CCR can be produced in a high yield with a 3,5-difluoro-6-aminopyridyl group-substituted quinolone derivative at the N-1 position through an easy process for industrial application. (cellular chemokine receptor) 5 It can be useful for the production of anti-infective agents as well as the preparation of a modulator (modulator).

Figure 112004039271831-pat00001
Figure 112004039271831-pat00001

상기 식에서, R1은 수소, 아미노 또는 메틸이고; R2는 불소, 염소, 메틸아미노, 2-하이드록시에틸아미노, N-메틸-N-(2-하이드록시에틸)아미노, 2-메톡시에틸 아미노 또는 (피롤리딘-3-일)아미노이며; W는 CH, N, CF, CCl, CBr, COCH3 또는 CCH3이다.Wherein R 1 is hydrogen, amino or methyl; R 2 is fluorine, chlorine, methylamino, 2-hydroxyethylamino, N-methyl-N- (2-hydroxyethyl) amino, 2-methoxyethyl amino or (pyrrolidin-3-yl) amino ; W is CH, N, CF, CCl, CBr, COCH 3 or CCH 3 .

Description

N-1 위치에 아미노피리딜기가 치환된 퀴놀론 유도체의 제조방법{PROCESS FOR PREPARATION OF QUINOLONE DERIVATIVES SUBSTITUTED BY AMINOPYRIDYL MOIETIES AT N-1 SITE}PROCESS FOR PREPARATION OF QUINOLONE DERIVATIVES SUBSTITUTED BY AMINOPYRIDYL MOIETIES AT N-1 SITE}

본 발명은 생리활성 물질의 주요한 중간체로서 CCR(세포화학수용체)5 모듈레이터(modulator) 및 감염증 치료제(anti-infective agents)의 제조 등에 유용한 N-1 위치에 아미노피리딜기가 치환된 퀴놀론 유도체를 제조하는 방법에 관한 것이다.The present invention is to prepare a quinolone derivative substituted with an aminopyridyl group at the N-1 position useful for the production of CCR (modulators) and anti-infective agents as a major intermediate of the bioactive substance It is about a method.

N-1 위치에 아미노피리딜기가 치환된 퀴놀론계 항균제 유도체는 우수한 항균력과 양호한 체내동태를 나타내는 생리활성 물질의 주요한 중간체로 이를 제조하기 위한 여러 방법들이 개발되어 왔다. 대표적인 N-1 위치에 아미노피리딜기가 치환된 퀴놀론계 항균제 유도체를 제조하는 기술로 하기 반응식 1에 나타난 바와 같은 공정이 대한민국 특허공개 제2000-53224호(우선권 주장 JP 1997-178462, JP 1996-317693)에 개시되어 있다. Quinolone-based antimicrobial derivatives having an aminopyridyl group substituted at the N-1 position have been developed as a major intermediate of physiologically active substances exhibiting excellent antimicrobial activity and good body dynamics. As a technique for preparing a quinolone antibacterial derivative having an aminopyridyl group substituted at a representative N-1 position, a process as shown in Scheme 1 is disclosed in Korean Patent Publication No. 2000-53224 (priority claim JP 1997-178462, JP 1996-317693). Is disclosed.

Figure 112004039271831-pat00002
Figure 112004039271831-pat00002

상기 식에서, X는 염소 또는 불소; R1은 수소, 아미노 또는 메틸; R2는 불소, 염소, 메틸아미노, 2-하이드록시에틸아미노, N-메틸-N-(2-하이드록시에틸)아미노, 2-메톡시에틸아미노 또는 (피롤리딘-3-일)아미노; 및 W는 CH, N, CF, CCl, CBr, COCH3 또는 CCH3이다.Wherein X is chlorine or fluorine; R 1 is hydrogen, amino or methyl; R 2 is fluorine, chlorine, methylamino, 2-hydroxyethylamino, N-methyl-N- (2-hydroxyethyl) amino, 2-methoxyethylamino or (pyrrolidin-3-yl) amino; And W is CH, N, CF, CCl, CBr, COCH 3 or CCH 3 .

그러나, 이러한 합성 방법은 고압반응기에서 가열하는, 산업적 효용성이 낮은 반응으로 제조된 2,6-다이아미노-3,5-다이플루오르피리딘(M. Ma 등, J. Chem. Soc. Perkin Transaction I, 817-821, 1980)을 사용하며, 2,6-다이아미노-3,5-다이플루오르피리딘이 도입된 중간체들의 용해도가 좋지 않아 N-1 위치에 아미노피리딜기가 치환된 퀴놀론계 항균제 유도체가 비효율적으로 제조되는 문제점이 있다.However, this synthesis method is a 2,6-diamino-3,5-difluoropyridine (M. Ma et al. , J. Chem. Soc. Perkin Transaction I , 817-821, 1980), and because of the poor solubility of intermediates introduced with 2,6-diamino-3,5-difluoropyridine, quinolone-based antimicrobial derivatives substituted with aminopyridyl groups at the N-1 position are inefficient. There is a problem to be manufactured.

본 발명의 목적은 산업적 적용이 용이한 공정에 의해 N-1 위치에 아미노피리딜기가 치환된 퀴놀론계 유도체를 제조하는 방법을 제공하는 것이다.
It is an object of the present invention to provide a method for preparing a quinolone derivative in which an aminopyridyl group is substituted at the N-1 position by an easy process for industrial application.

상기 목적에 따라, 본 발명에서는According to the above object, in the present invention

1) 하기 화학식 2의 3-옥소-프로피온산 에틸 에스테르 유도체를 트리에틸오르소포메이트와 반응시키는 단계;1) reacting the 3-oxo-propionic acid ethyl ester derivative of Formula 2 with triethylorthoformate;

2) 상기 단계 1에서 생성된 하기 화학식 3의 에톡시에틸렌 유도체를 2-아미노-3,5,6-트리플루오르피리딘과 반응시키는 단계;2) reacting the ethoxyethylene derivative of Formula 3 produced in Step 1 with 2-amino-3,5,6-trifluoropyridine;

3) 상기 단계 2에서 생성된 하기 화학식 4의 피리딜에나민 유도체를 유기용매 및 염기 존재하에 고리화 반응시킨 후 산가수분해하는 단계; 및3) acid hydrolysis of the pyridylenamin derivative of Formula 4 produced in step 2 in the presence of an organic solvent and a base, followed by cyclization; And

4) 상기 단계 3에서 생성된 하기 화학식 5의, N-1 위치에 3,5,6-트리플루오르피리딜기가 치환된 퀴놀론 유도체를, 암모니아수로 처리하여 아미노기를 도입시키는 단계를 포함하는, 하기 화학식 1의, N-1 위치에 3,5-다이플루오르-6-아미노피리딜기가 치환된 퀴놀론 유도체의 제조방법을 제공한다.4) a quinolone derivative having a 3,5,6-trifluoropyridyl group substituted in the N-1 position of the formula (5) generated in step 3, comprising the step of introducing an amino group by treatment with ammonia water, Provided is a method for producing a quinolone derivative having a 3,5-difluoro-6-aminopyridyl group substituted at the N-1 position.

<화학식 1><Formula 1>

Figure 112004039271831-pat00003
Figure 112004039271831-pat00003

Figure 112004039271831-pat00004
Figure 112004039271831-pat00004

Figure 112004039271831-pat00005
Figure 112004039271831-pat00005

Figure 112004039271831-pat00006
Figure 112004039271831-pat00006

Figure 112004039271831-pat00007
Figure 112004039271831-pat00007

상기 식에서, X는 염소 또는 불소; R1은 수소, 아미노 또는 메틸; R2는 불소, 염소, 메틸아미노, 2-하이드록시에틸아미노, N-메틸-N-(2-하이드록시에틸)아미 노, 2-메톡시에틸아미노 또는 (피롤리딘-3-일)아미노; 및 W는 CH, N, CF, CCl, CBr, COCH3 또는 CCH3이다.Wherein X is chlorine or fluorine; R 1 is hydrogen, amino or methyl; R 2 is fluorine, chlorine, methylamino, 2-hydroxyethylamino, N-methyl-N- (2-hydroxyethyl) amino, 2-methoxyethylamino or (pyrrolidin-3-yl) amino ; And W is CH, N, CF, CCl, CBr, COCH 3 or CCH 3 .

이하, 본 발명을 상세히 설명한다.Hereinafter, the present invention will be described in detail.

본 발명은 에톡시에틸렌 유도체와 아미노피리딜 유도체를 반응시키는데 있어서, 기존에 사용되어온 2,6-다이아미노-3,5-다이플루오르피리딘 대신에 2-아미노-3,5,6-트리플루오르피리딘을 사용한 후 나중에 아미노기를 도입함을 특징으로 한다.In the present invention, in reacting an ethoxyethylene derivative with an aminopyridyl derivative, 2-amino-3,5,6-trifluoropyridine is used instead of 2,6-diamino-3,5-difluoropyridine. It is characterized by introducing an amino group after using.

본 발명의 제조방법은 하기 반응식 2와 같이 나타낼 수 있다.The preparation method of the present invention can be represented by the following scheme 2.

Figure 112004039271831-pat00008
Figure 112004039271831-pat00008

상기 식에서, X, R1, R2 및 W는 전술한 바와 동일하다.Wherein X, R 1 , R 2 and W are the same as described above.

구체적으로, 본 발명의 단계 1은 에톡시에틸렌 유도체(화합물 3)를 제조하는 통상의 방법(대한민국 특허공개 제2000-53224호)에 따라 3-옥소-프로피온산 에틸 에스테르 유도체(화합물 2)을 트리에틸오르소포메이트와 반응시킨다.Specifically, step 1 of the present invention is triethyl to 3-oxo-propionic acid ethyl ester derivative (Compound 2) according to a conventional method for preparing an ethoxyethylene derivative (Compound 3) (Korean Patent Publication No. 2000-53224). React with orthoformate.

본 발명의 단계 2에서는 상기 단계 1에서 생성된 에톡시에틸렌 유도체(화합물 3)를 기존 방법에서 사용되어온 2,6-다이아미노-3,5-다이플루오르피리딘 대신에 2-아미노-3,5,6-트리플루오르피리딘과 반응시킨다. 이때 2-아미노-3,5,6-트리플루오르피리딘은 시판 물질을 상업적으로 구입하여 이용할 수도 있고, 바람직하게는 예를 들면 하기 반응식 3에 나타낸 바와 같이 2,3,5,6-테트라플루오르피리딘에 히드라지노기를 도입시킨 후 수소로 환원시키는 온화한 반응조건으로 제조하여 이용할 수 있다.In step 2 of the present invention, the ethoxyethylene derivative (compound 3) produced in step 1 is substituted with 2-amino-3,5, instead of 2,6-diamino-3,5-difluoropyridine, which has been used in conventional methods. React with 6-trifluoropyridine. In this case, 2-amino-3,5,6-trifluoropyridine may be commercially available from commercially available materials, and preferably 2,3,5,6-tetrafluoropyridine, for example, as shown in Scheme 3 below. The hydrazino group may be introduced into and then used under mild reaction conditions for reducing with hydrogen.

Figure 112004039271831-pat00009
Figure 112004039271831-pat00009

2-아미노-3,5,6-트리플루오르피리딘은 화합물 3을 기준으로 1 내지 4 당량, 바람직하게는 1.2 내지 2 당량 범위로 사용할 수 있다. 또한, 단계 2에서는 용매로서 메탄올, 에탄올, n-프로판올, i-프로판올, n-부탄올, i-부탄올 및 t-부탄올 등의 저급알콜이 사용가능하며, 용매는 화합물 3을 기준으로 3 내지 15 중량배, 바람직하게는 2 내지 7 중량배 범위로 사용할 수 있다. 단계 2의 반응은 10 내지 100℃, 바람직하게는 20 내지 40℃에서 2 내지 10시간, 바람직하게는 2 내지 8시간 동안 수행할 수 있다. 2-amino-3,5,6-trifluoropyridine can be used in the range of 1 to 4 equivalents, preferably 1.2 to 2 equivalents based on compound 3. Further, in step 2, lower alcohols such as methanol, ethanol, n-propanol, i-propanol, n-butanol, i-butanol and t-butanol may be used as the solvent, and the solvent may be 3 to 15 weight based on compound 3. Pear, preferably in the range of 2 to 7 weight times. The reaction of step 2 may be carried out at 10 to 100 ° C., preferably at 20 to 40 ° C. for 2 to 10 hours, preferably 2 to 8 hours.

단계 3의 사용가능한 염기로는 탄산칼륨, 탄산나트륨, 불화칼륨, 불화나트륨 및 소디움히드리드 등이 있으며, 화합물 4를 기준으로 1 내지 10 당량, 바람직하게는 2 내지 8 당량 범위로 사용할 수 있다. 단계 4의 유기용매의 양은 화합물 4를 기준으로 10 내지 30 중량배, 바람직하게는 12 내지 20 중량배 범위로 사용될 수 있다. 이렇게 고리화하여 얻어진 N-1 위치에 3,5,6-트리플루오르피리딜기가 치환된 퀴놀론 유도체 에스테르는 상기 단계 2와 동일한 저급 알콜용매 중에서 산가수분해하는데, 이때 사용되는 산으로는 염산이 바람직하며 산 및 저급 알콜의 양은 각각 독립적으로 N-1 위치에 3,5,6-트리플루오르피리딜기가 치환된 퀴놀론 유도체 에스테르를 기준으로 10 내지 30 중량배, 바람직하게는 15 내지 20 중량배 범위로 사용될 수 있다. 또한, 단계 3의 산가수분해 반응은 50 내지 120℃에서 수행될 수 있다.Usable bases of step 3 include potassium carbonate, sodium carbonate, potassium fluoride, sodium fluoride, sodium hydride and the like, and can be used in the range of 1 to 10 equivalents, preferably 2 to 8 equivalents based on compound 4. The amount of the organic solvent of step 4 may be used in the range of 10 to 30 times by weight, preferably 12 to 20 times by weight, based on compound 4. The quinolone derivative ester in which the 3,5,6-trifluoropyridyl group is substituted at the N-1 position thus obtained by cyclization is acid hydrolyzed in the same lower alcohol solvent as in step 2, wherein hydrochloric acid is preferable as the acid used. The amount of the acid and the lower alcohol is independently 10 to 30 times by weight, preferably 15 to 20 times by weight, based on the quinolone derivative ester having 3,5,6-trifluoropyridyl group substituted at the N-1 position. Can be used. In addition, the acid hydrolysis reaction of step 3 may be carried out at 50 to 120 ℃.

단계 4의 알콜용매 또한 상기 단계 2에서 사용가능한 저급 알콜용매와 동일하며, 화합물 5를 기준으로 20 내지 40 중량배, 바람직하게는 20 내지 30 중량배 범위로 사용할 수 있다. 또한, 단계 4에서, 암모니아수는 28%로 희석하여 사용하는 것이 바람직하며, 화합물 6을 기준으로 3 내지 20 당량, 바람직하게는 5 내지 12 당량 범위로 사용할 수 있다. 단계 4의 반응은 0 내지 40℃, 바람직하게는 15 내지 30℃에서 10 내지 30시간, 바람직하게는 10 내지 20시간 동안 수행할 수 있다. The alcohol solvent of step 4 is also the same as the lower alcohol solvent usable in step 2, and may be used in the range of 20 to 40 weight times, preferably 20 to 30 weight times based on compound 5. In addition, in step 4, ammonia water is preferably used diluted to 28%, it can be used in the range of 3 to 20 equivalents, preferably 5 to 12 equivalents based on compound 6. The reaction of step 4 may be carried out for 10 to 30 hours, preferably 10 to 20 hours at 0 to 40 ℃, preferably 15 to 30 ℃.

이하, 본 발명을 실시예에 의해 상세히 설명한다.Hereinafter, the present invention will be described in detail by way of examples.

단, 하기 실시예는 본 발명을 예시하는 것일 뿐, 본 발명의 내용이 하기 실시예에 한정되는 것은 아니다.However, the following examples are merely to illustrate the invention, but the content of the present invention is not limited to the following examples.

실시예 1: 1-(3,5-다이플루오르-6-아미노피리딘-2-일)-6-플루오르-7-클로로-4-옥소-1,4-다이하이드로[1,8]-나프티리딘-3-카복실산의 제조Example 1: 1- (3,5-Difluoro-6-aminopyridin-2-yl) -6-fluoro-7-chloro-4-oxo-1,4-dihydro [1,8] -naphthyridine Preparation of 3-carboxylic acid

<단계 1> 3-(2,6-다이클로로-5-플루오르피리딘-3-카보닐)-3-에톡시아크릴산 에틸 에스테르의 제조<Step 1> Preparation of 3- (2,6-dichloro-5-fluoropyridine-3-carbonyl) -3-ethoxyacrylic acid ethyl ester

3-(2,6-다이클로로-5-플루오르피리딘-3-일)-3-옥소-프로피온산 에틸 에스테르(LG Chem) 30 g을 초산 무수물 30 ㎖에 녹인 후 트리에틸오르소포메이트 26.7 ㎖를 가하여 2시간 동안 가열 환류시켰으며, 감압여과하여 용매를 제거하고 표제화합물 32.6 g을 얻었다.30 g of 3- (2,6-dichloro-5-fluoropyridin-3-yl) -3-oxo-propionic acid ethyl ester (LG Chem) was dissolved in 30 ml of acetic anhydride, and 26.7 ml of triethylorthoformate was added thereto. The mixture was heated to reflux for 2 hours, filtered off under reduced pressure to give 32.6 g of the title compound.

1H-NMR(200MHz, CDCl3):δ 1.12 (3H, t, J = 7.1Hz), 1.48 (3H, t, J = 7.1Hz), 4.14 (2H, q, J = 7.1Hz), 4.40 (2H, q, J = 7.1Hz), 7.54 (1H, d, J = 7.1Hz), 7.87 (1H, s)1 H-NMR (200 MHz, CDCl 3): δ 1.12 (3H, t, J = 7.1 Hz), 1.48 (3H, t, J = 7.1 Hz), 4.14 (2H, q, J = 7.1 Hz), 4.40 (2H, q, J = 7.1 Hz), 7.54 (1H, d, J = 7.1 Hz), 7.87 (1H, s)

<단계 2> 3-(2,6-다이클로로-5-플루오르피리딘-3-카보닐)-3-(3,5,6-트리플루오르피 리딘-2-일아미노)아크릴산 에틸 에스테르의 제조<Step 2> Preparation of 3- (2,6-dichloro-5-fluoropyridine-3-carbonyl) -3- (3,5,6-trifluoropyridin-2-ylamino) acrylic acid ethyl ester

상기 단계 1에서 얻어진 3-(2,6-다이클로로-5-플루오르피리딘-3-카보닐)-3-에톡시아크릴산 에틸 에스테르 8.04 g에 에탄올 20 ㎖을 가하여 10℃ 이하로 냉각시킨 후, 여기에 3-아미노-3,5,6-트리플루오르피리딘 3.54 g을 에탄올 20 ㎖에 녹인 용액을 천천히 가하였다. 이를 실온에서 2시간 동안 교반시킨 후 여과하고 에탄올 10 ㎖로 세척한 후 건조하여 표제 화합물 9.44 g을 얻었다.20 ml of ethanol was added to 8.04 g of 3- (2,6-dichloro-5-fluoropyridine-3-carbonyl) -3-ethoxyacrylic acid ethyl ester obtained in step 1, followed by cooling to 10 ° C. or lower, and then To a solution of 3.54 g of 3-amino-3,5,6-trifluoropyridine in 20 ml of ethanol was slowly added. It was stirred at room temperature for 2 hours, filtered, washed with 10 ml of ethanol and dried to give 9.44 g of the title compound.

1H-NMR(300MHz, CDCl3):δ 0.97 & 1.18 (3H, t, J = 7.5), 4.10-4.21 (2H, m), 7.42-7.62 (2H, m), 8.02 & 8.06 (1H, d, J = 12Hz), 11.55 & 12.70 (1H, d, J = 12Hz)1 H-NMR (300 MHz, CDCl 3): δ 0.97 & 1.18 (3H, t, J = 7.5), 4.10-4.21 (2H, m), 7.42-7.62 (2H, m), 8.02 & 8.06 (1H, d, J = 12 Hz), 11.55 & 12.70 (1H, d, J = 12 Hz)

<단계 3> 1-(3,5,6-트리플루오르피리딘-2-일)-6-플루오르-7-클로로-4-옥소-1,4-다이하이드로-[1,8]-나프티리딘-3-카복실산 에틸 에스테르의 제조<Step 3> 1- (3,5,6-Trifluoropyridin-2-yl) -6-fluoro-7-chloro-4-oxo-1,4-dihydro- [1,8] -naphthyridine- Preparation of 3-carboxylic acid ethyl ester

상기 단계 2에서 얻어진 3-(2,6-다이클로로-5-플루오르피리딘-3-카보닐)-3-(3,5,6-트리플루오르피리딘-2-일아미노)아크릴산 에틸 에스테르 9.4 g을 다이메틸포름아미드 50 ㎖에 녹인 후 탄산칼륨 2.08 ㎎을 가하여 70-75℃에서 1시간 동안 반응시켰다. 반응혼합물을 증류수 100 ㎖에 분산시킨 후 생성된 고체를 여과하여 증류수 50 ㎖ 및 에탄올 20 ㎖로 세척하였으며 이를 건조시켜 목적화합물 7.1 g을 얻었다.9.4 g of 3- (2,6-dichloro-5-fluoropyridine-3-carbonyl) -3- (3,5,6-trifluoropyridin-2-ylamino) acrylic acid ethyl ester obtained in step 2 was added. After dissolving in 50 ml of dimethylformamide, 2.08 mg of potassium carbonate was added and reacted at 70-75 ° C. for 1 hour. The reaction mixture was dispersed in 100 mL of distilled water and the resulting solid was filtered and washed with 50 mL of distilled water and 20 mL of ethanol and dried to obtain 7.1 g of the target compound.

1H-NMR(300MHz, CDCl3):δ 1.41 (3H, t, J = 7.2Hz), 4.42 (2H, q, J = 7.2Hz), 7.75 (1H, q, J = 7.2Hz), 8.47 (1H, d, J = 7.2Hz), 8.67 (1H, s)1 H-NMR (300 MHz, CDCl 3): δ 1.41 (3H, t, J = 7.2 Hz), 4.42 (2H, q, J = 7.2 Hz), 7.75 (1H, q, J = 7.2 Hz), 8.47 (1H, d, J = 7.2 Hz), 8.67 (1H, s)

<단계 4> 1-(3,5,6-트리플루오르피리딘-2-일)-6-플루오르-7-클로로-4-옥소-1,4-다이하이드로[1,8]-나프티리딘-3-카복실산의 제조<Step 4> 1- (3,5,6-Trifluoropyridin-2-yl) -6-fluoro-7-chloro-4-oxo-1,4-dihydro [1,8] -naphthyridine-3 Preparation of Carboxylic Acids

상기 단계 3에서 얻은 1-(3,5,6-트리플루오르피리딘-2-일)-6-플루오르-7-클로로-4-옥소-1,4-다이하이드로-[1,8]-나프티리딘-3-카복실산 에틸 에스테르 6.9 g을 아이소프로판올 20 ㎖에 현탁시킨 후 6 N HCl 38 ㎖를 가하여 3시간 동안 환류 교반시켰다. 반응이 완결되면 이를 냉각하여 고체를 여과하였으며, 증류수 및 아세톤으로 세척 후 건조하여 목적화합물 6.38 g을 얻었다.1- (3,5,6-trifluoropyridin-2-yl) -6-fluoro-7-chloro-4-oxo-1,4-dihydro- [1,8] -naphthyridine obtained in step 3 above 6.9 g of 3-carboxylic acid ethyl ester was suspended in 20 ml of isopropanol, and 38 ml of 6 N HCl was added thereto, followed by stirring for 3 hours at reflux. When the reaction was completed, it was cooled and the solid was filtered, washed with distilled water and acetone and dried to obtain 6.38 g of the target compound.

1H-NMR(300MHz, DMSO-d6):δ 8.73-8.82 (2H, m), 9.16 (1H, s), 13.64 (1H, brs)1 H-NMR (300 MHz, DMSO-d 6): δ 8.73-8.82 (2H, m), 9.16 (1H, s), 13.64 (1H, brs)

<단계 5> 1-(3,5-다이플루오르-6-아미노피리딘-2-일)-6,7-다이플루오르-4-옥소-1,4-다이하이드로[1,8]-나프티리딘-3-카복실산의 제조Step 5 1- (3,5-Difluoro-6-aminopyridin-2-yl) -6,7-difluoro-4-oxo-1,4-dihydro [1,8] -naphthyridine- Preparation of 3-carboxylic Acid

상기 단계 4에서 얻은 1-(3,5,6-트리플루오르피리딘-2-일)-6-플루오르-7-클로로-4-옥소-1,4-다이하이드로-[1,8]-나프티리딘-3-카복실산 3 g을 아이소프로판올 80 ㎖ 및 염화메틸렌 40 ㎖의 혼합용액과 교반하면서 28% 암모니아수용액 60 ㎖를 적가한 후 30℃에서 15시간 동안 교반시켰다. 반응혼합물을 실온으로 냉각하고 여과한 여액을 감압 증발한 후, 얻어진 잔유물을 관크로마토그라피(용리액: 염화메틸렌:메탄올=20:1)로 분리하여 하얀 고체의 표제 화합물 2.25 g을 얻었다.1- (3,5,6-trifluoropyridin-2-yl) -6-fluoro-7-chloro-4-oxo-1,4-dihydro- [1,8] -naphthyridine obtained in step 4 above 3 g of -3-carboxylic acid was added dropwise with 80 ml of isopropanol and 40 ml of methylene chloride, and 60 ml of an aqueous 28% ammonia solution was added thereto, followed by stirring at 30 ° C for 15 hours. The reaction mixture was cooled to room temperature and the filtrate was filtered and evaporated under reduced pressure, and the obtained residue was separated by tube chromatography (eluent: methylene chloride: methanol = 20: 1) to obtain 2.25 g of a white solid title compound.

1H-NMR(300MHz, DMSO-d6):δ 8.71-8.74(1H, m), 9.16 (1H, s), 13.64 (1H, brs)1 H-NMR (300 MHz, DMSO-d 6): δ 8.71-8.74 (1 H, m), 9.16 (1 H, s), 13.64 (1 H, brs)

실시예 2: 1-(3,5,-다이플루오르-6-아미노피리딘-2-일)-6,7-다이플루오르-4-옥소-1,4-다이하이드로퀴놀린-3-카르복실산의 제조Example 2: of 1- (3,5, -difluoro-6-aminopyridin-2-yl) -6,7-difluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid Produce

<단계 1> 2,4,5-트리플루오르벤조일클로라이드의 제조<Step 1> Preparation of 2,4,5-trifluorobenzoyl chloride

2,4,5-트리플루오르벤조산(Fluorochem) 50 g을 건조된 염화메틸렌 350 ㎖에 용해시킨 후 정제한 티오닐클로라이드 26.9 ㎖ 및 다이메틸포름아마이드 0.5 ㎖을 가하여 70∼80℃에서 10시간 동안 반응시켰다. 반응 종료 후 감압 하에 용매 및 과량의 티오닐클로라이드를 제거하고, 잔여물을 감압증류하여 무색의 표제화합물 48.97 ㎖를 얻었다.50 g of 2,4,5-trifluorobenzoic acid (Fluorochem) was dissolved in 350 ml of dried methylene chloride, and then 26.9 ml of purified thionyl chloride and 0.5 ml of dimethylformamide were added thereto, followed by reaction at 70 to 80 ° C for 10 hours. I was. After completion of the reaction, the solvent and excess thionyl chloride were removed under reduced pressure, and the residue was distilled under reduced pressure to give 48.97 ml of a colorless title compound.

끓는점(20 mmHg) ; 65∼70℃Boiling point (20 mmHg); 65 ~ 70 ℃

<단계 2> 2-(2,4,5-트리플루오르벤조일)말론산 다이에틸 에스테르의 제조<Step 2> Preparation of 2- (2,4,5-trifluorobenzoyl) malonic acid diethyl ester

마그네슘 조각 14.9 g을 무수 에탄올 44 ㎖에 현탁시킨 후 사염화탄소 4 ㎖을 가하여 45℃에서 10분간 교반반응 시켰다. 여기에 다이에틸 말로네이트 92.7 ㎖, 무수 에탄올 60 ㎖ 및 톨루엔 330 ㎖의 혼합물을 50 내지 60℃의 온도에서 적가하였으며, 동일 온도에서 1시간 동안 교반시킨 후 -10℃로 냉각시켰다. 상기 단계 1에서 생성된 2,4,5-트리플루오르벤조일클로라이드 108.5 g을 무수 톨루엔 60 ㎖에 희석시킨 용액을 반응혼합물에 적가하여 0 내지 5℃에서 1시간 동안 교반하였으며, 이를 상온에서 하룻밤동안 방치하였다. 얼음물 300 ㎖에 진한 황산 12.67 ㎖을 희석시킨 수용액을 가하여 유기층을 분리하였으며, 물층을 톨루엔 200 ㎖로 2회 추출하고 남은 유기층을 소금물로 세척하였다. 무수 황산 마그네슘으로 건조시킨 후 감압 하에 용매를 제거하였으며, 남은 시럽상의 물질을 50℃ 고진공중에서 건조시켜 표제화합물 288 g을 얻었다. 이 화합물은 정제하지 않고 다음 반응에 그대로 사용하였다. 14.9 g of magnesium pieces were suspended in 44 ml of anhydrous ethanol, and 4 ml of carbon tetrachloride was added thereto, followed by stirring for 10 minutes at 45 ° C. A mixture of 92.7 ml of diethyl malonate, 60 ml of anhydrous ethanol, and 330 ml of toluene was added dropwise at a temperature of 50 to 60 ° C, stirred for 1 hour at the same temperature, and then cooled to -10 ° C. A solution of 108.5 g of 2,4,5-trifluorobenzoyl chloride produced in step 1, diluted in 60 ml of anhydrous toluene was added dropwise to the reaction mixture, and stirred for 1 hour at 0 to 5 ° C., which was left at room temperature overnight. It was. An aqueous layer of 12.67 ml of concentrated sulfuric acid was added to 300 ml of ice water, and the organic layer was separated. The aqueous layer was extracted twice with 200 ml of toluene, and the remaining organic layer was washed with brine. After drying over anhydrous magnesium sulfate, the solvent was removed under reduced pressure, and the remaining syrup-like material was dried in a high vacuum at 50 ° C. to obtain 288 g of the title compound. This compound was used as it was for the next reaction without purification.

<단계 3> 3-옥소-3-(2,4,5-트리플루오르페닐)프로피온산 에틸 에스테르의 제조<Step 3> Preparation of 3-oxo-3- (2,4,5-trifluorophenyl) propionic acid ethyl ester

상기 단계 2에서 얻은 2-(2,4,5-트리플루오르벤조일)말론산 다이에틸 에스테르 51.3 g을 물 150 ㎖에 가한 후 촉매량의 톨루엔술폰산 0.6 g을 첨가하여 6시간 동안 강하게 교반하면서 환류시켰다. 반응액을 상온으로 냉각시킨 후 염화메틸렌 100 ㎖로 추출하였으며, 물층을 같은 용매로 2회 더 추출하고 남은 유기층을 무수 황산 마그네슘으로 건조시켰다. 감압 하에 용매를 증발시킨 후 유상의 화합물을 얻었으며, 이를 감압 증류하여 백색 결정상인 표제 화합물 174.6 g을 얻었다.51.3 g of 2- (2,4,5-trifluorobenzoyl) malonic acid diethyl ester obtained in step 2 was added to 150 ml of water, and then 0.6 g of a catalytic amount of toluenesulfonic acid was added thereto, followed by reflux with vigorous stirring for 6 hours. The reaction solution was cooled to room temperature, extracted with 100 ml of methylene chloride, the aqueous layer was extracted two more times with the same solvent, and the remaining organic layer was dried over anhydrous magnesium sulfate. After evaporation of the solvent under reduced pressure, an oily compound was obtained, which was distilled under reduced pressure to obtain 174.6 g of the title compound as a white crystalline phase.

끓는점(0.05 mmHg): 85∼90℃, 녹는점: 50℃Boiling point (0.05 mmHg): 85 to 90 ° C, Melting point: 50 ° C

<단계 4> 3-에톡시-2-(2,4,5-트리플루오르벤조일)아크릴산 에틸 에스테르의 제조Step 4 Preparation of 3-ethoxy-2- (2,4,5-trifluorobenzoyl) acrylic acid ethyl ester

상기 단계 3에서 얻은 3-옥소-3-(2,4,5-트리플루오르페닐)프로피온산 에틸 에스테르 24.6 g과 트리에틸오르토포메이트 30.4 ㎖ 및 아세트산 무수물 34.5 ㎖를 혼합하여 150℃에서 12시간 동안 가열 및 교반 반응시켰다. 반응혼합물을 150℃에서 증류 생성물이 없어질 때 까지 증류 시킨 후, 온도를 120℃로 내리고 감압증발기로 용매를 증류하여 표제 화합물 29.0 g을 얻었다. 이를 정제하지 않고 다음 반응에 그대로 사용하였다.24.6 g of 3-oxo-3- (2,4,5-trifluorophenyl) propionic acid ethyl ester obtained in step 3, 30.4 ml of triethylorthoformate and 34.5 ml of acetic anhydride were mixed and heated at 150 ° C. for 12 hours. And stirred. After distilling the reaction mixture at 150 ° C. until the distillation product disappeared, the temperature was lowered to 120 ° C. and the solvent was distilled off under reduced pressure to obtain 29.0 g of the title compound. It was used as it was for the next reaction without purification.

<단계 5> 2-(2,4,5-트리플루오르벤조일)-3-(3,5,6-트리플루오르피리딘-2-일)아미노아크릴산 에틸 에스테르의 제조Step 5 Preparation of 2- (2,4,5-trifluorobenzoyl) -3- (3,5,6-trifluoropyridin-2-yl) aminoacrylic acid ethyl ester

상기 단계 4에서 생성된 3-에톡시-2-(2,4,5-트리플루오르벤조일)아크릴산 에틸 에스테르 7.65 g에 에탄올 20 ㎖를 가하여 10℃ 이하로 냉각시켰으며, 2-아미노-3,5,6-트리플루오르피리딘 3.75 g을 에탄올 20 ㎖에 녹인 용액을 천천히 가하였다. 이를 실온에서 2시간 동안 교반시킨 후 여과하였으며, 에탄올 10㎖로 세척하고 건조하여 표제 화합물 9.04 g을 얻었다. To 7.65 g of 3-ethoxy-2- (2,4,5-trifluorobenzoyl) acrylic acid ethyl ester produced in step 4, 20 ml of ethanol was added and cooled to 10 ° C or lower, and 2-amino-3,5 A solution of 3.75 g of, 6-trifluoropyridine in 20 ml of ethanol was slowly added. It was stirred at room temperature for 2 hours and then filtered, washed with 10 ml of ethanol and dried to give 9.04 g of the title compound.

1H-NMR(300MHz, CDCl3): δ 1.20 (3H, t, J = 7.5Hz), 4.19 (2H, q, J = 7.5Hz), 6.87-6.95 (1H, m), 7.31-7.39 (1H, m), 7.54 (1H, q, J = 7.5Hz), 8.94 (1H, d, J = 12Hz), 12.43 (1H, d, J = 12Hz)1 H-NMR (300 MHz, CDCl 3): δ 1.20 (3H, t, J = 7.5 Hz), 4.19 (2H, q, J = 7.5 Hz), 6.87-6.95 (1H, m), 7.31-7.39 (1H, m ), 7.54 (1H, q, J = 7.5 Hz), 8.94 (1H, d, J = 12 Hz), 12.43 (1H, d, J = 12 Hz)

<단계 6> 1-(3,5,6-트리플루오르피리딘-2-일)-6,7-다이플루오르-4-옥소-1,4-다이하이드로퀴놀린-3-카르복실산 에틸 에스테르의 제조Step 6 Preparation of 1- (3,5,6-trifluoropyridin-2-yl) -6,7-difluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid ethyl ester

상기 단계 5에서 얻은 2-(2,4,5-트리플루오르벤조일)-3-(3,5,6-트리플루오르피리딘-2-일)아미노아크릴산 에틸 에스테르 9.04 g을 실온에서 DMF 120 ㎖에 녹인 후 불소화나트륨 1.69 g을 가하여 130℃에서 10시간 동안 가열 교반시켰다. 이를 실온으로 식힌 후 물 200 ㎖을 가하여 생성된 침전물을 여과하였으며, 이를 관크로마토그라피(용리액: 에틸 아세테이트:헥산=1:2)로 분리하여 하얀 고체의 표제 화합물 7.4 g을 얻었다.9.04 g of 2- (2,4,5-trifluorobenzoyl) -3- (3,5,6-trifluoropyridin-2-yl) aminoacrylic acid ethyl ester obtained in step 5 was dissolved in 120 ml of DMF at room temperature. Then, 1.69 g of sodium fluoride was added thereto, and the mixture was heated and stirred at 130 ° C. for 10 hours. After cooling to room temperature, 200 ml of water was added thereto, and the resulting precipitate was filtered and separated by tube chromatography (eluent: ethyl acetate: hexane = 1: 2) to obtain 7.4 g of the title compound as a white solid.

1H-NMR(300MHz, CDCl3): δ 1.40 (3H, t, J = 7.2Hz), 4.40 (2H, q, J = 7.2Hz), 6.77-6.83 (1H, m), 7.84 (1H, q, J = 7.2Hz), 8.31(1H, dd, J1 = 8.6Hz, J2 = 10.1Hz), 8.46 (1H, d, J = 0.3Hz)1 H-NMR (300 MHz, CDCl 3): δ 1.40 (3H, t, J = 7.2 Hz), 4.40 (2H, q, J = 7.2 Hz), 6.77-6.83 (1H, m), 7.84 (1H, q, J = 7.2 Hz), 8.31 (1H, dd, J1 = 8.6 Hz, J2 = 10.1 Hz), 8.46 (1H, d, J = 0.3 Hz)

<단계 7> 1-(3,5-다이플루오르-6-히드라지노피리딘-2-일)-6,7-다이플루오르-4-옥소-1,4-다이하이드로퀴놀린-3-카르복실산의 제조<Step 7> of 1- (3,5-difluoro-6-hydrazinopyridin-2-yl) -6,7-difluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid Produce

상기 단계 6에서 얻은 1-(3,5,6-트리플루오르피리딘-2-일)-6,7-다이플루오르-4-옥소-1,4-다이하이드로퀴놀린-3-카르복실산 에틸에스테르 5.4 g을 아이소프로판올 30 ㎖에 현탁시킨 후 6 N HCl 30 ㎖를 가하여 3시간 동안 환류 교반시켰다. 반응혼합물을 냉각하여 생성된 고체를 여과하였으며, 이를 증류수 및 아세톤으로 세척하고 건조하여 표제화합물 3.4 g을 얻었다.1- (3,5,6-trifluoropyridin-2-yl) -6,7-difluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid ethyl ester obtained in step 6 above 5.4 The suspension was suspended in 30 ml of isopropanol, and 30 ml of 6N HCl was added thereto, followed by stirring for 3 hours at reflux. The reaction mixture was cooled and the resulting solid was filtered, which was washed with distilled water and acetone and dried to obtain 3.4 g of the title compound.

1H-NMR(300MHz, DMSO-d6): δ 7.85 (1H, dd, J1 = 6.6Hz, J2 = 11.7Hz), 8.33 (1H, dd, J1 = 8.7Hz, J2 = 10.2Hz), 8.83 (1H, dd, J1 = 8.4Hz, J2 = 16.2Hz), 9.17 (1H, s), 14.13 (1H, brs)1 H-NMR (300 MHz, DMSO-d6): δ 7.85 (1H, dd, J1 = 6.6 Hz, J2 = 11.7 Hz), 8.33 (1H, dd, J1 = 8.7 Hz, J2 = 10.2 Hz), 8.83 (1H, dd, J1 = 8.4 Hz, J2 = 16.2 Hz), 9.17 (1H, s), 14.13 (1H, brs)

<단계 8> 1-(3,5-다이플루오르-6-아미노피리딘-2-일)-6,7-다이플루오르-4-옥소-1,4-다이하이드로퀴놀린-3-카르복실산의 제조Step 8 Preparation of 1- (3,5-Difluoro-6-aminopyridin-2-yl) -6,7-difluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid

상기 단계 7에서 얻은 1-(3,5-다이플루오르-6-히드라지노피리딘-2-일)-6,7-다이플루오르-4-옥소-1,4-다이하이드로퀴놀린-3-카르복실산 2.0 g을 아이소프로판올 80 ㎖ 및 염화메틸렌 40 ㎖의 혼합용액에 가한 후, 이를 교반하면서 28% 암모니아수용액 60 ㎖를 적가하여 30℃에서 20시간 동안 교반시켰다. 반응혼합물을 실온으로 냉각하고 여과한 여액을 감압 증발하였으며, 잔유물을 관크로마토그라피(용리액: 염화메틸렌:메탄올=20:1)로 분리하여 하얀 고체의 표제 화합물 0.78 g을 얻었다.1- (3,5-Difluoro-6-hydrazinopyridin-2-yl) -6,7-difluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid obtained in step 7 above 2.0 g was added to a mixed solution of 80 ml of isopropanol and 40 ml of methylene chloride, and then 60 ml of an aqueous 28% ammonia solution was added dropwise with stirring, followed by stirring at 30 ° C. for 20 hours. The reaction mixture was cooled to room temperature, and the filtrate was filtered and evaporated under reduced pressure. The residue was separated by tube chromatography (eluent: methylene chloride: methanol = 20: 1) to obtain 0.78 g of a white solid title compound.

1H-NMR(300MHz, DMSO-d6): δ 6.78 (2H, s), 7.55 (1H, m), 8.02 (1H, m), 8.18 (1H, m), 8.64(1H, s)1 H-NMR (300 MHz, DMSO-d6): δ 6.78 (2H, s), 7.55 (1H, m), 8.02 (1H, m), 8.18 (1H, m), 8.64 (1H, s)

실시예 3: 1-(3,5-다이플루오르-6-아미노피리딘-2-일)-6,7-다이플루오르-8-메톡시-4-옥소-1,4-다이하이드로퀴놀린-3-카르복실산의 제조Example 3: 1- (3,5-Difluoro-6-aminopyridin-2-yl) -6,7-difluoro-8-methoxy-4-oxo-1,4-dihydroquinoline-3- Preparation of Carboxylic Acids

2,4,5-트리플루오르-3-메톡시벤조산(Fluorochem) 103 g을 출발물질로 사용하여 실시예 2와 동일한 방법으로 1-(3,5-다이플루오르피리딘-6-아미노-2-일)-6,7-다이플루오르-8-메톡시-4-옥소-1,4-다이하이드로퀴놀린-3-카르복실산 38.6 g을 제조하였다.1- (3,5-difluoropyridin-6-amino-2-yl in the same manner as in Example 2, using 103 g of 2,4,5-trifluoro-3-methoxybenzoic acid (Fluorochem) as a starting material 38.6 g of 6,7-difluoro-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid were prepared.

1H-NMR(300MHz, CDCl3): δ 4.00(3H, s), 6.73(2H, s), 7.91(1H, m), 8.18 (1H, m), 8.62(1H, s) 1 H-NMR (300 MHz, CDCl 3): δ 4.00 (3H, s), 6.73 (2H, s), 7.91 (1H, m), 8.18 (1H, m), 8.62 (1H, s)

실시예 4: 1-(3,5-다이플루오르-6-아미노피리딘-2-일)-6-플루오르-7-메틸아미노-8-클로로-4-옥소-1,4-다이하이드로퀴놀린-3-카르복실산의 제조Example 4: 1- (3,5-Difluoro-6-aminopyridin-2-yl) -6-fluoro-7-methylamino-8-chloro-4-oxo-1,4-dihydroquinoline-3 Preparation of Carboxylic Acids

<단계 1> 1-(3,5,6-트리플루오르피리딘-2-일)-6,7-다이플루오르-8-클로로-4-옥소-1,4-다이하이드로퀴놀린-3-카르복실산의 제조<Step 1> 1- (3,5,6-trifluoropyridin-2-yl) -6,7-difluoro-8-chloro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid Manufacture

2,4,5-트리플루오르-3-클로로벤조산(Fluorochem) 35.0 g을 출발물질로 사용 하여 실시예 2의 단계 1 내지 7의 방법에 따라 1-(3,5,6-트리플루오르피리딘-2-일)-6,7-다이플루오르-8-클로로-4-옥소-1,4-다이하이드로퀴놀린-3-카르복실산 27.7 g을 제조하였다.1- (3,5,6-trifluoropyridine-2 according to the method of steps 1 to 7 of Example 2 using 35.0 g of 2,4,5-trifluoro-3-chlorobenzoic acid (Fluorochem) as starting material 27.7 g of -yl) -6,7-difluoro-8-chloro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid were prepared.

1H-NMR(300MHz, CDCl3): δ 3.65(3H, s), 7.78 (1H, d), 8.12 (1H, s), 8.18 (1H, m), 8.54(1H, s), 8.701 H-NMR (300 MHz, CDCl 3): δ 3.65 (3H, s), 7.78 (1H, d), 8.12 (1H, s), 8.18 (1H, m), 8.54 (1H, s), 8.70

<단계 2> 1-(3,5,6-트리플루오르피리딘-2-일)-6-플루오르-7-메틸아미노-8-클로로-4-옥소-1,4-다이하이드로퀴놀린-3-카르복실산의 제조<Step 2> 1- (3,5,6-trifluoropyridin-2-yl) -6-fluoro-7-methylamino-8-chloro-4-oxo-1,4-dihydroquinoline-3-car Preparation of Acids

단계 1에서 생성된 1-(3,5,6-트리플루오르피리딘-2-일)-6,7-다이플루오르-8-클로로-4-옥소-1,4-다이하이드로퀴놀린-3-카르복실산 3.90 g을 아이소프로판올 50 ㎖에 가한 후 교반하면서 40% 메틸아민수용액 20 ㎖를 적가한 다음, 30℃에서 20시간 동안 교반하였다. 반응혼합물을 실온으로 냉각하고 여과한 여액을 감압 증발하였으며, 잔유물을 관크로마토그라피(용리액: 염화메틸렌:메탄올=20:1)로 분리하여 하얀 고체의 목적 화합물 3.78 g을 얻었다.1- (3,5,6-trifluoropyridin-2-yl) -6,7-difluoro-8-chloro-4-oxo-1,4-dihydroquinoline-3-carboxyl produced in step 1 3.90 g of acid was added to 50 ml of isopropanol, and 20 ml of 40% aqueous methylamine solution was added dropwise while stirring, followed by stirring at 30 DEG C for 20 hours. The reaction mixture was cooled to room temperature, and the filtrate was filtered and evaporated under reduced pressure. The residue was separated by tube chromatography (eluent: methylene chloride: methanol = 20: 1) to obtain 3.78 g of a white solid target compound.

1H-NMR(300MHz, DMSO-d6): δ 3.09(3H, dd, J=5Hz, J=8Hz), 6.28 (1H, m), 6.72(2H, brs), 7.90(1H, t, J=10Hz), 8.47 (1H, s)1 H-NMR (300 MHz, DMSO-d6): δ 3.09 (3H, dd, J = 5 Hz, J = 8 Hz), 6.28 (1H, m), 6.72 (2H, brs), 7.90 (1H, t, J = 10 Hz ), 8.47 (1 H, s)

<단계 3> 1-(3,5-다이플루오르-6-아미노피리딘-2-일)-6-플루오르-7-메틸아미노-8-클로로-4-옥소-1,4-다이하이드로퀴놀린-3-카르복실산의 제조Step 3 1- (3,5-Difluoro-6-aminopyridin-2-yl) -6-fluoro-7-methylamino-8-chloro-4-oxo-1,4-dihydroquinoline-3 Preparation of Carboxylic Acids

상기 단계 2에서 얻은 1-(3,5,6-트리플루오르피리딘-2-일)-6-플루오르-7-메틸아미노-8-클로로-4-옥소-1,4-다이하이드로퀴놀린-3-카르복실산 2.02 g을 출발물질로 사용하여 실시예 2의 단계 8의 방법에 따라 1-(3,5-다이플루오르-6-아미노피리딘-2-일)-6-플루오르-7-메틸아미노-8-클로로-4-옥소-1,4-다이하이드로퀴놀린-3-카르복실산 1.62 g을 제조하였다.1- (3,5,6-trifluoropyridin-2-yl) -6-fluoro-7-methylamino-8-chloro-4-oxo-1,4-dihydroquinoline-3- obtained in step 2 above 1- (3,5-Difluoro-6-aminopyridin-2-yl) -6-fluoro-7-methylamino- according to the method of step 8 of Example 2 using 2.02 g of carboxylic acid as starting material 1.62 g of 8-chloro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid was prepared.

1H-NMR(300MHz, DMSO-d6): δ 3.09(3H, dd, J=5Hz, J=8Hz), 6.28(1H, m), 6.72(2H, brs), 7.55(1H, brs), 8.10(1H, m), 8.63 (1H, s) 1 H-NMR (300 MHz, DMSO-d6): δ 3.09 (3H, dd, J = 5 Hz, J = 8 Hz), 6.28 (1H, m), 6.72 (2H, brs), 7.55 (1H, brs), 8.10 ( 1H, m), 8.63 (1H, s)

실시예 5: 1-(3,5-다이플루오르-6-아미노피리딘-2-일)-5-아미노-6,8-다이플루오르-7-메틸아미노-4-옥소-1,4-다이하이드로퀴놀린-3-카르복실산의 제조Example 5: 1- (3,5-Difluoro-6-aminopyridin-2-yl) -5-amino-6,8-difluoro-7-methylamino-4-oxo-1,4-dihydro Preparation of Quinoline-3-carboxylic Acid

2,3,4,5-테트라플루오르-6-아미노벤조산(화학연) 84 g을 출발물질로 사용하여 실시예 4와 동일한 방법으로 1-(3,5-다이플루오르-6-아미노피리딘-2-일)-5-아미노-6,8-다이플루오르-7-메틸아미노-4-옥소-1,4-다이하이드로퀴놀린-3-카르복실산 64.3 g을 제조하였다.84 g of 2,3,4,5-tetrafluoro-6-aminobenzoic acid (chemical lead) was used as a starting material, and 1- (3,5-difluoro-6-aminopyridine-2- 64.3 g of 1) -5-amino-6,8-difluoro-7-methylamino-4-oxo-1,4-dihydroquinoline-3-carboxylic acid were prepared.

1H-NMR(300MHz, DMSO-d6): δ 3.09(3H, dd, J=5Hz, J=8Hz), 6.26(1H, m), 6.72(2H, brs), 7.57(1H, brs), 7.90(1H, m), 8.47 (1H, s)1 H-NMR (300 MHz, DMSO-d6): δ 3.09 (3H, dd, J = 5 Hz, J = 8 Hz), 6.26 (1H, m), 6.72 (2H, brs), 7.57 (1H, brs), 7.90 ( 1H, m), 8.47 (1H, s)

실시예 6: 1-(3,5-다이플루오르-6-아미노피리딘-2-일)-5-메틸-6-플루오르-7-메틸아미노-8-브로모-4-옥소-1,4-다이하이드로퀴놀린-3-카르복실산의 제조Example 6: 1- (3,5-Difluoro-6-aminopyridin-2-yl) -5-methyl-6-fluoro-7-methylamino-8-bromo-4-oxo-1,4- Preparation of Dihydroquinoline-3-carboxylic Acid

2,4,5-트리플루오르-3-브로모-6-메틸벤조산(화학연) 38.6 g을 출발물질로 사용하여 실시예 4와 동일한 방법으로 1-(3,5-다이플루오르-6-아미노피리딘-2-일)-5-메틸-6-플루오르-7-메틸아미노-8-브로모-4-옥소-1,4-다이하이드로퀴놀린-3-카르복실산 18.28 g을 제조하였다.1- (3,5-difluoro-6-aminopyridine in the same manner as in Example 4 using 38.6 g of 2,4,5-trifluoro-3-bromo-6-methylbenzoic acid (chemical lead) as a starting material 18.28 g of 2-yl) -5-methyl-6-fluoro-7-methylamino-8-bromo-4-oxo-1,4-dihydroquinoline-3-carboxylic acid were prepared.

1H-NMR(300MHz, DMSO-d6): δ 2.02(3H, s), 3.09(3H, dd, J=5Hz, J=8Hz), 6.28 (1H, m), 6.72 (2H, brs), 7.55 (1H, brs), 8.48 (1H, s)1 H-NMR (300 MHz, DMSO-d6): δ 2.02 (3H, s), 3.09 (3H, dd, J = 5 Hz, J = 8 Hz), 6.28 (1H, m), 6.72 (2H, brs), 7.55 ( 1H, brs), 8.48 (1H, s)

실시예 7: 1-(3,5-다이플루오르-6-아미노피리딘-2-일)-6-플루오르-7-{N-메틸-N-(2-히드록시에틸)}아미노-8-클로로-4-옥소-1,4-다이하이드로퀴놀린-3-카르복실산의 제조Example 7: 1- (3,5-Difluoro-6-aminopyridin-2-yl) -6-fluoro-7- {N-methyl-N- (2-hydroxyethyl)} amino-8-chloro Preparation of 4-oxo-1,4-dihydroquinoline-3-carboxylic acid

<단계 1> 1-(3,5,6-트리플루오르피리딘-2-일)-6,7-다이플루오르-8-클로로-4-옥소-1,4-다이하이드로퀴놀린-3-카르복실산의 제조<Step 1> 1- (3,5,6-trifluoropyridin-2-yl) -6,7-difluoro-8-chloro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid Manufacture

2,4,5-트리플루오르-3-클로로벤조산(Fluorochem) 42.0 g을 출발물질로 사용하여 실시예 2의 단계 1 내지 7에 제시된 방법에 따라 1-(3,5,6-트리플루오르피리 딘-2-일)-6,7-다이플루오르-8-클로로-4-옥소-1,4-다이하이드로퀴놀린-3-카르복실산 31.3 g을 제조하였다.1- (3,5,6-trifluoropyridine) according to the method given in steps 1 to 7 of Example 2 using 42.0 g of 2,4,5-trifluoro-3-chlorobenzoic acid (Fluorochem) as starting material 31.3 g of 2-yl) -6,7-difluoro-8-chloro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid were prepared.

1H-NMR(300MHz, CDCl3): δ 3.65(3H, s), 7.78 (1H, d), 8.12 (1H, s), 8.18 (1H, m), 8.54(1H, s), 8.701 H-NMR (300 MHz, CDCl 3): δ 3.65 (3H, s), 7.78 (1H, d), 8.12 (1H, s), 8.18 (1H, m), 8.54 (1H, s), 8.70

<단계 2> 1-(3,5,6-트리플루오르피리딘-2-일)-6-플루오르-7-{N-메틸-N-(2-히드록시에틸)}아미노-8-클로로-4-옥소-1,4-다이하이드로퀴놀린-3-카르복실산의 제조<Step 2> 1- (3,5,6-trifluoropyridin-2-yl) -6-fluoro-7- {N-methyl-N- (2-hydroxyethyl)} amino-8-chloro-4 Preparation of -oxo-1,4-dihydroquinoline-3-carboxylic acid

상기 단계 1에서 생성된 1-(3,5,6-트리플루오르피리딘-2-일)-6,7-다이플루오르-8-클로로-4-옥소-1,4-다이하이드로퀴놀린-3-카르복실산 3.90 g을 아이소프로판올 50 ㎖에 녹인 후 이를 교반하면서 N-메틸-N-(2-히드록시에틸)아민 2.1 g을 가하여 30℃에서 20시간 동안 교반시켰다. 반응혼합물을 실온으로 냉각하고 여과한 여액을 감압 증발하였으며, 잔유물을 관크로마토그라피(용리액: 염화메틸렌:메탄올=20:1)로 분리하여 하얀 고체의 표제 화합물 3.91 g을 얻었다.1- (3,5,6-trifluoropyridin-2-yl) -6,7-difluoro-8-chloro-4-oxo-1,4-dihydroquinoline-3-car generated in step 1 above 3.90 g of acid was dissolved in 50 ml of isopropanol, and 2.1 g of N-methyl-N- (2-hydroxyethyl) amine was added thereto with stirring, followed by stirring at 30 ° C for 20 hours. The reaction mixture was cooled to room temperature and the filtrate was filtered and evaporated under reduced pressure, and the residue was separated by tube chromatography (eluent: methylene chloride: methanol = 20: 1) to obtain 3.91 g of a white solid of the title compound.

1H-NMR(300MHz, DMSO-d6): δ 2.09(3H, s), 3.57(2H, m), 3.82(2H, m), 5.30(1H, brs), 7.64 (1H, brs), 8.14(1H, m), 8.63 (1H, s)1 H-NMR (300 MHz, DMSO-d6): δ 2.09 (3H, s), 3.57 (2H, m), 3.82 (2H, m), 5.30 (1H, brs), 7.64 (1H, brs), 8.14 (1H , m), 8.63 (1H, s)

<단계 3> 1-(3,5-다이플루오르-6-아미노피리딘-2-일)-6-플루오르-7-{N-메틸-N-(2-히드록시에틸)}아미노-8-클로로-4-옥소-1,4-다이하이드로퀴놀린-3-카르복실산의 제조<Step 3> 1- (3,5-Difluoro-6-aminopyridin-2-yl) -6-fluoro-7- {N-methyl-N- (2-hydroxyethyl)} amino-8-chloro Preparation of 4-oxo-1,4-dihydroquinoline-3-carboxylic acid

상기 단계 2에서 생성된 1-(3,5,6-트리플루오르피리딘-2-일)-6-플루오르-7-{N-메틸-N-(2-히드록시에틸)}아미노-8-클로로-4-옥소-1,4-다이하이드로퀴놀린-3-카르복실산 3.10 g을 출발물질로 사용하여 실시예 2의 단계 8과 동일한 방법으로 1-(3,5-다이플루오르-6-아미노피리딘-2-일)-6-플루오르-7-{N-메틸-N-(2-히드록시에틸)}아미노-8-클로로-4-옥소-1,4-다이하이드로퀴놀린-3-카르복실산 2.42 g을 제조하였다.1- (3,5,6-trifluoropyridin-2-yl) -6-fluoro-7- {N-methyl-N- (2-hydroxyethyl)} amino-8-chloro produced in step 2 above 1- (3,5-Difluoro-6-aminopyridine in the same manner as in Step 8 of Example 2, using 3.10 g of 4-oxo-1,4-dihydroquinoline-3-carboxylic acid as starting material -2-yl) -6-fluoro-7- {N-methyl-N- (2-hydroxyethyl)} amino-8-chloro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 2.42 g were prepared.

1H-NMR(300MHz, DMSO-d6): δ 2.09(3H, s), 3.57(2H, m), 3.82(2H, m), 5.30(1H, brs), 6.78(2H, s), 7.55 (1H, brs), 8.14(1H, m), 8.63 (1H, s)1 H-NMR (300 MHz, DMSO-d6): δ 2.09 (3H, s), 3.57 (2H, m), 3.82 (2H, m), 5.30 (1H, brs), 6.78 (2H, s), 7.55 (1H , brs), 8.14 (1H, m), 8.63 (1H, s)

실시예 8: 1-(3,5-다이플루오르-6-아미노피리딘-2-일)-6-플루오르-7-(2-메톡시에틸)아미노-8-클로로-4-옥소-1,4-다이하이드로퀴놀린-3-카르복실산의 제조Example 8: 1- (3,5-Difluoro-6-aminopyridin-2-yl) -6-fluoro-7- (2-methoxyethyl) amino-8-chloro-4-oxo-1,4 Preparation of -dihydroquinoline-3-carboxylic acid

<단계 1> 1-(3,5,6-트리플루오르피리딘-2-일)-6-플루오르-7-(2-메톡시에틸)아미노-8-클로로-4-옥소-1,4-다이하이드로퀴놀린-3-카르복실산의 제조<Step 1> 1- (3,5,6-trifluoropyridin-2-yl) -6-fluoro-7- (2-methoxyethyl) amino-8-chloro-4-oxo-1,4-di Preparation of Hydroquinoline-3-carboxylic Acid

상기 실시예 7의 단계 1에서 생성된 1-(3,5,6-트리플루오르피리딘-2-일)-6,7-다이플루오르-8-클로로-4-옥소-1,4-다이하이드로퀴놀린-3-카르복실산 2.67 g을 아이소프로판올 50 ㎖에 넣고 교반하면서 2-메톡시에틸아민 2.1 g을 가하여 30℃에 서 20시간동안 교반하였다. 반응혼합물을 실온으로 냉각하고 여과한 여액을 감압 증발하였으며, 잔유물을 관크로마토그라피(용리액: 염화메틸렌:메탄올=20:1)로 분리하여 하얀 고체의 표제 화합물 2.21 g을 얻었다.1- (3,5,6-trifluoropyridin-2-yl) -6,7-difluoro-8-chloro-4-oxo-1,4-dihydroquinoline produced in step 1 of Example 7 above 2.67 g of -3-carboxylic acid was added to 50 ml of isopropanol, and 2.1 g of 2-methoxyethylamine was added thereto under stirring, followed by stirring at 30 DEG C for 20 hours. The reaction mixture was cooled to room temperature, and the filtrate was filtered and evaporated under reduced pressure, and the residue was separated by tube chromatography (eluent: methylene chloride: methanol = 20: 1) to give 2.21 g of the title compound as a white solid.

1H-NMR(300MHz, DMSO-d6): δ 2.64(2H, m), 3.41(2H,s), 3.54(3H, m), 4.86 (1H, m), 7.75(1H, m), 7.94(1H, m), 8.8.52(1H, s)1 H-NMR (300 MHz, DMSO-d6): δ 2.64 (2H, m), 3.41 (2H, s), 3.54 (3H, m), 4.86 (1H, m), 7.75 (1H, m), 7.94 (1H , m), 8.8.52 (1 H, s)

<단계 2> 1-(3,5-다이플루오르-6-아미노피리딘-2-일)-6-플루오르-7-(2-메톡시에틸)아미노-8-클로로-4-옥소-1,4-다이하이드로퀴놀린-3-카르복실산의 제조<Step 2> 1- (3,5-Difluoro-6-aminopyridin-2-yl) -6-fluoro-7- (2-methoxyethyl) amino-8-chloro-4-oxo-1,4 Preparation of -dihydroquinoline-3-carboxylic acid

상기 단계 1에서 생성된 1-(3,5,6-트리플루오르피리딘-2-일)-6-플루오르-7-(2-메톡시에틸)아미노-8-클로로-4-옥소-1,4-다이하이드로퀴놀린-3-카르복실산 3.10 g을 사용하여 50℃에서 실시예 2의 단계 8과 동일한 방법으로 1-(3,5-다이플루오르-6-아미노피리딘-2-일)-6-플루오르-7-(2-메톡시에틸)아미노-8-클로로-4-옥소-1,4-다이하이드로퀴놀린-3-카르복실산 2.42 g을 제조하였다.1- (3,5,6-trifluoropyridin-2-yl) -6-fluoro-7- (2-methoxyethyl) amino-8-chloro-4-oxo-1,4 produced in step 1 above 1- (3,5-Difluoro-6-aminopyridin-2-yl) -6- in the same manner as in step 8 of Example 2, at 50 ° C using 3.10 g of -dihydroquinoline-3-carboxylic acid 2.42 g of fluor-7- (2-methoxyethyl) amino-8-chloro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid were prepared.

1H-NMR(300MHz, DMSO-d6): δ 2.64(2H, m), 3.41(2H,s), 3.54(3H, s), 4.86 (1H, m), 6.72(2H, m), 7.62(1H, m), 7.94(1H, m), 8.8.52(1H, s)1 H-NMR (300 MHz, DMSO-d6): δ 2.64 (2H, m), 3.41 (2H, s), 3.54 (3H, s), 4.86 (1H, m), 6.72 (2H, m), 7.62 (1H) , m), 7.94 (1H, m), 8.8.52 (1H, s)

실시예 9: 1-(3,5-다이플루오르-6-아미노피리딘-2-일)-6-플루오르-7-(2-히드록시에틸)아미노-8-클로로-4-옥소-1,4-다이하이드로퀴놀린-3-카르복실산의 제조Example 9: 1- (3,5-Difluoro-6-aminopyridin-2-yl) -6-fluoro-7- (2-hydroxyethyl) amino-8-chloro-4-oxo-1,4 Preparation of -dihydroquinoline-3-carboxylic acid

<단계 1> 1-(3,5,6-트리플루오르피리딘-2-일)-6-플루오르-7-(2-히드록시에틸)아미노-8-클로로-4-옥소-1,4-다이하이드로퀴놀린-3-카르복실산의 제조<Step 1> 1- (3,5,6-trifluoropyridin-2-yl) -6-fluoro-7- (2-hydroxyethyl) amino-8-chloro-4-oxo-1,4-di Preparation of Hydroquinoline-3-carboxylic Acid

상기 실시예 7의 단계 1에서 생성된 1-(3,5,6-트리플루오르피리딘-2-일)-6,7-다이플루오르-8-클로로-4-옥소-1,4-다이하이드로퀴놀린-3-카르복실산 1.39 g을 아이소프로판올 30 ㎖에 녹인 후 교반하면서 2-히드록시에틸아민 1.4 g을 가하여 30℃에서 20시간 동안 교반하였다. 반응혼합물을 실온으로 냉각하고 여과한 여액을 감압 증발하였으며, 잔유물을 관크로마토그라피(용리액: 염화메틸렌:메탄올=20:1)로 분리하여 하얀 고체의 표제 화합물 1.41 g을 얻었다.1- (3,5,6-trifluoropyridin-2-yl) -6,7-difluoro-8-chloro-4-oxo-1,4-dihydroquinoline produced in step 1 of Example 7 above 1.39 g of -3-carboxylic acid was dissolved in 30 ml of isopropanol, and 1.4 g of 2-hydroxyethylamine was added thereto under stirring, followed by stirring at 30 ° C for 20 hours. The reaction mixture was cooled to room temperature and the filtrate was filtered and evaporated under reduced pressure, and the residue was separated by tube chromatography (eluent: methylene chloride: methanol = 20: 1) to obtain 1.41 g of a white solid title compound.

1H-NMR(300MHz, DMSO-d6): δ 3.09(3H, dd, J=5Hz, J=8Hz), 6.28 (1H, m), 6.72(2H, brs), 7.90(1H, t, J=10Hz), 8.47 (1H, s)1 H-NMR (300 MHz, DMSO-d6): δ 3.09 (3H, dd, J = 5 Hz, J = 8 Hz), 6.28 (1H, m), 6.72 (2H, brs), 7.90 (1H, t, J = 10 Hz ), 8.47 (1 H, s)

<단계 2> 1-(3,5-다이플루오르-6-아미노피리딘-2-일)-6-플루오르-7-(2-히드록시에틸)아미노-8-클로로-4-옥소-1,4-다이하이드로퀴놀린-3-카르복실산의 제조<Step 2> 1- (3,5-Difluoro-6-aminopyridin-2-yl) -6-fluoro-7- (2-hydroxyethyl) amino-8-chloro-4-oxo-1,4 Preparation of -dihydroquinoline-3-carboxylic acid

상기 단계 1에서 얻은 1-(3,5,6-트리플루오르피리딘-2-일)-6-플루오르-7-(2-히드록시에틸)아미노-8-클로로-4-옥소-1,4-다이하이드로퀴놀린-3-카르복실산 2.15 g을 출발물질로 사용하여 실시예 2의 단계 8에 제시된 방법에 따라 1-(3,5-다이플루오르-6-아미노피리딘-2-일)-6-플루오르-7-(2-히드록시에틸)아미노-8-클로로-4-옥 소-1,4-다이하이드로퀴놀린-3-카르복실산 1.78 g을 제조하였다.1- (3,5,6-trifluoropyridin-2-yl) -6-fluoro-7- (2-hydroxyethyl) amino-8-chloro-4-oxo-1,4- obtained in step 1 above. 1- (3,5-Difluoro-6-aminopyridin-2-yl) -6- according to the method given in step 8 of Example 2 using 2.15 g of dihydroquinoline-3-carboxylic acid as starting material 1.78 g of fluor-7- (2-hydroxyethyl) amino-8-chloro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid were prepared.

1H-NMR(300MHz, DMSO-d6): δ 2.64(2H, m), 3.41(2H, m), 4.86(1H, brs), 5.44(2H, brs), 7.90(1H, m), 7.94(1H, brs), 8.49(1H, m)1 H-NMR (300 MHz, DMSO-d6): δ 2.64 (2H, m), 3.41 (2H, m), 4.86 (1H, brs), 5.44 (2H, brs), 7.90 (1H, m), 7.94 (1H) , brs), 8.49 (1H, m)

실시예 10: 1-(3,5-다이플루오르-6-아미노피리딘-2-일)-6-플루오르-7-(피롤리딘-3-일)아미노-8-클로로-4-옥소-1,4-다이하이드로퀴놀린-3-카르복실산의 제조Example 10 1- (3,5-Difluoro-6-aminopyridin-2-yl) -6-fluoro-7- (pyrrolidin-3-yl) amino-8-chloro-4-oxo-1 Preparation of 4,4-dihydroquinoline-3-carboxylic acid

<단계 1> 1-(3,5,6-트리플루오르피리딘-2-일)-6-플루오르-7-(피롤리딘-3-일)아미노-8-클로로-4-옥소-1,4-다이하이드로퀴놀린-3-카르복실산의 제조 Step 1 1- (3,5,6-trifluoropyridin-2-yl) -6-fluoro-7- (pyrrolidin-3-yl) amino-8-chloro-4-oxo-1,4 Preparation of -dihydroquinoline-3-carboxylic acid

상기 실시예 7의 단계 1에서 생성된 1-(3,5,6-트리플루오르피리딘-2-일)-6,7-다이플루오르-8-클로로-4-옥소-1,4-다이하이드로퀴놀린-3-카르복실산 2.80 g을 아이소프로판올 30 ㎖에 녹인 후, 교반하면서 3-아미노피롤리딘 2.10 g을 가하여 30℃에서 20시간 동안 교반시켰다. 반응혼합물을 실온으로 냉각하고 여과한 여액을 감압 증발하였으며, 잔유물을 관크로마토그라피(용리액: 염화메틸렌:메탄올=20:1)로 분리하여 하얀 고체의 표제 화합물 2.74 g을 얻었다.1- (3,5,6-trifluoropyridin-2-yl) -6,7-difluoro-8-chloro-4-oxo-1,4-dihydroquinoline produced in step 1 of Example 7 above 2.80 g of -3-carboxylic acid was dissolved in 30 ml of isopropanol, and then 2.10 g of 3-aminopyrrolidine was added thereto with stirring, followed by stirring at 30 ° C. for 20 hours. The reaction mixture was cooled to room temperature, the filtrate was filtered and evaporated under reduced pressure, and the residue was separated by tube chromatography (eluent: methylene chloride: methanol = 20: 1) to give 2.74 g of a white solid of the title compound.

1H-NMR(300MHz, DMSO-d6): δ 3.09(3H, dd, J=5Hz, J=8Hz), 6.28 (1H, m), 6.72(2H, brs), 7.90(1H, t, J=10Hz), 8.47 (1H, s)1 H-NMR (300 MHz, DMSO-d6): δ 3.09 (3H, dd, J = 5 Hz, J = 8 Hz), 6.28 (1H, m), 6.72 (2H, brs), 7.90 (1H, t, J = 10 Hz ), 8.47 (1 H, s)

<단계 2> 1-(3,5-다이플루오르-6-아미노피리딘-2-일)-6-플루오르-7-(피롤리딘-3-일)아미노-8-클로로-4-옥소-1,4-다이하이드로퀴놀린-3-카르복실산의 제조<Step 2> 1- (3,5-Difluoro-6-aminopyridin-2-yl) -6-fluoro-7- (pyrrolidin-3-yl) amino-8-chloro-4-oxo-1 Preparation of 4,4-dihydroquinoline-3-carboxylic acid

상기 단계 1에서 얻은 1-(3,5,6-트리플루오르피리딘-2-일)-6-플루오르-7-(피롤리딘-3-일)아미노-8-클로로-4-옥소-1,4-다이하이드로퀴놀린-3-카르복실산 2.65 g을 출발물질로 사용하여 실시예 2의 단계 8에 제시된 방법에 따라 1-(3,5-다이플루오르-6-아미노피리딘-2-일)-6-플루오르-7-(피롤리딘-3-일)아미노-8-클로로-4-옥소-1,4-다이하이드로퀴놀린-3-카르복실산 2.31 g을 제조하였다.1- (3,5,6-trifluoropyridin-2-yl) -6-fluoro-7- (pyrrolidin-3-yl) amino-8-chloro-4-oxo-1 obtained in step 1, 1- (3,5-Difluoro-6-aminopyridin-2-yl)-according to the method given in step 8 of Example 2 using 2.65 g of 4-dihydroquinoline-3-carboxylic acid as starting material 2.31 g of 6-fluoro-7- (pyrrolidin-3-yl) amino-8-chloro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid were prepared.

1H-NMR(300MHz, DMSO-d6): δ 1.75(2H, m), 2.07(1H,m), 2.85-3.07(4H, brs), 4.43(1H,m), 5.92(1H, m), 6.77(2H, brs), 7.96(1H, brs), 7.99(1H, m), 8.69(1H, s) 1 H-NMR (300 MHz, DMSO-d6): δ 1.75 (2 H, m), 2.07 (1 H, m), 2.85-3.07 (4 H, brs), 4.43 (1 H, m), 5.92 (1 H, m), 6.77 (2H, brs), 7.96 (1H, brs), 7.99 (1H, m), 8.69 (1H, s)

실시예 11: 1-(3,5-다이플루오르-6-아미노피리딘-2-일)-6,7-다이플루오르-8-메틸-4-옥소-1,4-다이하이드로퀴놀린-3-카르복실산의 제조Example 11: 1- (3,5-Difluoro-6-aminopyridin-2-yl) -6,7-difluoro-8-methyl-4-oxo-1,4-dihydroquinoline-3-car Preparation of Acids

2,4,5-트리플루오르-3-메틸벤조산(Fluorochem) 25.9 g을 출발물질로 사용하여 실시예 2의 방법에 따라 (3,5-다이플루오르피리딘-6-아미노-2-일)-6,7-다이플루오르-8-메틸-4-옥소-1,4-다이하이드로퀴놀린-3-카르복실산 7.92 g을 제조하였다.(3,5-Difluoropyridin-6-amino-2-yl) -6 according to the method of Example 2 using 25.9 g of 2,4,5-trifluoro-3-methylbenzoic acid (Fluorochem) as starting material 7.92 g of, 7-difluoro-8-methyl-4-oxo-1,4-dihydroquinoline-3-carboxylic acid was prepared.

1H-NMR(300MHz, DMSO-d6): δ 2.09(3H, s), 6.28 (1H, m), 6.72(2H, brs), 7.90(1H, t, J=10Hz), 8.47 (1H, s)1 H-NMR (300 MHz, DMSO-d6): δ 2.09 (3H, s), 6.28 (1H, m), 6.72 (2H, brs), 7.90 (1H, t, J = 10 Hz), 8.47 (1H, s)

상기에서 살펴본 바와 같이, 본 발명에 따른 제조방법은 기존에 사용되어온 2,6-다이아미노-3,5-다이플루오르피리딘 대신에 2-아미노-3,5,6-트리플루오르피리딘을 반응시킨 후 아미노기를 추가 도입함으로써 N-1 위치에 3,5-다이플루오르-6-아미노피리딜기가 치환된 퀴놀론 유도체를 고수율로 제조할 수 있으므로 생리활성 물질의 주요한 중간체로서 CCR(cellular chemokine receptor: 세포화학수용체)5 모듈레이터(modulator)의 제조 뿐 아니라 감염증 치료제(anti-infective agents) 제조 등에 유용하게 활용될 수 있다.As described above, in the preparation method according to the present invention, after reacting 2-amino-3,5,6-trifluoropyridine instead of 2,6-diamino-3,5-difluoropyridine, which has been conventionally used, By introducing an additional amino group, a quinolone derivative having a 3,5-difluoro-6-aminopyridyl group substituted at the N-1 position can be prepared in high yield, and thus a cellular chemokine receptor (CCR) is a major intermediate of a bioactive substance. It can be useful for the preparation of receptor) 5 modulators as well as for the preparation of anti-infective agents.

Claims (1)

1) 하기 화학식 2의 3-옥소-프로피온산 에틸 에스테르 유도체를 트리에틸오르소포메이트와 반응시키는 단계; 1) reacting the 3-oxo-propionic acid ethyl ester derivative of Formula 2 with triethylorthoformate; 2) 상기 단계 1에서 생성된 하기 화학식 3의 에톡시에틸렌 유도체를 2-아미노-3,5,6-트리플루오르피리딘과 반응시키는 단계; 2) reacting the ethoxyethylene derivative of Formula 3 produced in Step 1 with 2-amino-3,5,6-trifluoropyridine; 3) 상기 단계 2에서 생성된 하기 화학식 4의 피리딜에나민 유도체를 유기용매 및 염기 존재하에 고리화 반응시킨 후 산가수분해하는 단계; 및 3) acid hydrolysis of the pyridylenamin derivative of Formula 4 produced in step 2 in the presence of an organic solvent and a base, followed by cyclization; And 4) 상기 단계 3에서 생성된 하기 화학식 5의, N-1 위치에 3,5,6-트리플루오르피리딜기가 치환된 퀴놀론 유도체를, 암모니아수로 처리하여 아미노기를 도입시키는 단계를 포함하는, 하기 화학식 1의, N-1 위치에 3,5-다이플루오르-6-아미노피리딜기가 치환된 퀴놀론 유도체의 제조방법:4) a quinolone derivative having a 3,5,6-trifluoropyridyl group substituted in the N-1 position of the formula (5) generated in step 3, comprising the step of introducing an amino group by treatment with ammonia water, Method for preparing a quinolone derivative having 1, 3,5-difluoro-6-aminopyridyl group substituted at the N-1 position: <화학식 1><Formula 1>
Figure 112004039271831-pat00010
Figure 112004039271831-pat00010
<화학식 2><Formula 2>
Figure 112004039271831-pat00011
Figure 112004039271831-pat00011
<화학식 3><Formula 3>
Figure 112004039271831-pat00012
Figure 112004039271831-pat00012
<화학식 4><Formula 4>
Figure 112004039271831-pat00013
Figure 112004039271831-pat00013
<화학식 5><Formula 5>
Figure 112004039271831-pat00014
Figure 112004039271831-pat00014
상기 식에서, X는 염소 또는 불소이고; R1은 수소, 아미노 또는 메틸이고; R2는 불소, 염소, 메틸아미노, 2-하이드록시에틸아미노, N-메틸-N-(2-하이드록시에틸)아미노, 2-메톡시에틸아미노 또는 (피롤리딘-3-일)아미노이고; W는 CH, N, CF, CCl, CBr, COCH3 또는 CCH3이다.Wherein X is chlorine or fluorine; R 1 is hydrogen, amino or methyl; R 2 is fluorine, chlorine, methylamino, 2-hydroxyethylamino, N-methyl-N- (2-hydroxyethyl) amino, 2-methoxyethylamino or (pyrrolidin-3-yl) amino ; W is CH, N, CF, CCl, CBr, COCH 3 or CCH 3 .
KR1020040068860A 2004-08-31 2004-08-31 Process for preparation of quinolone derivatives substituted by aminopyridyl moieties at n-1 site KR100589429B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020040068860A KR100589429B1 (en) 2004-08-31 2004-08-31 Process for preparation of quinolone derivatives substituted by aminopyridyl moieties at n-1 site

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020040068860A KR100589429B1 (en) 2004-08-31 2004-08-31 Process for preparation of quinolone derivatives substituted by aminopyridyl moieties at n-1 site

Publications (2)

Publication Number Publication Date
KR20060020106A KR20060020106A (en) 2006-03-06
KR100589429B1 true KR100589429B1 (en) 2006-06-14

Family

ID=37127297

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020040068860A KR100589429B1 (en) 2004-08-31 2004-08-31 Process for preparation of quinolone derivatives substituted by aminopyridyl moieties at n-1 site

Country Status (1)

Country Link
KR (1) KR100589429B1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110194738B (en) * 2019-06-03 2022-04-05 华侨大学 Preparation method of 1,2, 3-trisubstituted 4-quinolone derivative

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR920006780B1 (en) * 1990-08-16 1992-08-17 제일약품 주식회사 Quinolnone carboxcylic acid derivatives
KR950005301B1 (en) * 1990-09-04 1995-05-23 주식회사대웅제약 Novel quinolone carbocylic acid deriverjives
KR950014567B1 (en) * 1991-08-01 1995-12-08 주식회사대웅제약 Novel quinolone carboxylic acid derivatives
KR960001721B1 (en) * 1991-07-16 1996-02-03 주식회사대웅제약 Novel quinolone carboxylic acid derivatives
KR960001919B1 (en) * 1993-02-24 1996-02-06 제일약품주식회사 Novel quinolone carboxylic acid derivatives and its
US5519016A (en) 1992-05-27 1996-05-21 Ube Industries, Ltd. Aryl group- or aromatic heterocyclic group-substituted aminoquinolone derivatives and anti-HIV agent

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR920006780B1 (en) * 1990-08-16 1992-08-17 제일약품 주식회사 Quinolnone carboxcylic acid derivatives
KR950005301B1 (en) * 1990-09-04 1995-05-23 주식회사대웅제약 Novel quinolone carbocylic acid deriverjives
KR960001721B1 (en) * 1991-07-16 1996-02-03 주식회사대웅제약 Novel quinolone carboxylic acid derivatives
KR950014567B1 (en) * 1991-08-01 1995-12-08 주식회사대웅제약 Novel quinolone carboxylic acid derivatives
US5519016A (en) 1992-05-27 1996-05-21 Ube Industries, Ltd. Aryl group- or aromatic heterocyclic group-substituted aminoquinolone derivatives and anti-HIV agent
KR960001919B1 (en) * 1993-02-24 1996-02-06 제일약품주식회사 Novel quinolone carboxylic acid derivatives and its

Also Published As

Publication number Publication date
KR20060020106A (en) 2006-03-06

Similar Documents

Publication Publication Date Title
EP0265230B1 (en) Substituted-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acids, derivatives thereof, pharmaceutical compositions comprising the compounds, and processes for producing the compounds
FR2563521A1 (en) 1,4-DIHYDRO-4-OXONAPHTYRIDINE DERIVATIVES AND THEIR SALTS, PROCESS FOR THEIR PRODUCTION AND ANTIBACTERIAL AGENTS CONTAINING SAME
US5281612A (en) Naphthyridine antibacterial agents
JPH0826003B2 (en) Intermediates for the production of antibacterial agents
KR101420892B1 (en) Process for the preparation of Imatinib and intermediates thereof
KR102018929B1 (en) Process for the preparation of (5-fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl)-acetic acid esters
NO166080B (en) ANALOGY PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE 5,6,8-TRIFLUORKINOLINES.
HU204258B (en) Process for producing intermediates for producing quinoline derivatives of antibacterial activity
US5097032A (en) Antibacterial agents - II
KR100589429B1 (en) Process for preparation of quinolone derivatives substituted by aminopyridyl moieties at n-1 site
IL97617A (en) Preparation of 2, 4, 5-trihalo-beta-ketobenzene (and pyridine) propanoic acid esters for use in preparing quinolone antibiotics
CA2465686C (en) Process for the preparation of 4-(8-chloro-5,6-dihydro-11h-benzo(5,6)-cyclohepta-(1,2b)-pyridin-11-ylidene)-1-piperidinecarboxylic acid ethyl ester (loratadine)
EA007497B1 (en) Improved method of making nevirapine
AU776300B2 (en) Synthesis of 3-amino-3-aryl propanoates
KR20060020082A (en) Process for preparation of 2-aminopyridine derivatives
JPS61189271A (en) Production of 1-methyl-5-hydroxypyrazole
KR100571690B1 (en) [1S-[1a,2b,3b,4a(S*)]]-4-[[3-amino-4-[[1-(3-chloro-2-thienyl)methyl]propyl]amino]-2-pyridinyl]amino]-N-ethyl-2,3-dihydroxycyclopentanecarboxamide, preparation of said compound and preparation of the dihydrochloride salt thereof
AU2002340487A1 (en) Process for the preparation of 4-(8-chloro-5,6-dihydro-11H-benzo(5,6)-cyclohepta-(1,2b)-pyridin-11-ylidene)-1-piperidinecarboxylic acid ethyl ester (loratadine)
JP4616770B2 (en) Selective amino substituent introduction method
JP2005510486A (en) Process for producing β-ketoester compound
JPS6172753A (en) Pyridyl ketone derivative
AU2019260015A1 (en) Process for the hydrolysis of quinolone carboxylic esters
KR930006078B1 (en) Preparation of beta-ketoester
US20050182259A1 (en) Novel process for preparing 3-fluoroquinolines
WO2004108680A1 (en) Intermediates and process for thr production of optically active quinolonecarboxylic acid derivatives

Legal Events

Date Code Title Description
A201 Request for examination
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20110411

Year of fee payment: 6

FPAY Annual fee payment

Payment date: 20120111

Year of fee payment: 8

LAPS Lapse due to unpaid annual fee